Rituximab in refractory chronic inflammatory demyelinating polyneuropathy

Area of Science:

• Neurology
• Immunology
• Clinical Therapeutics

Background:

• Chronic inflammatory demyelinating polyneuropathy (CIDP) is a neurological disorder requiring early intervention to prevent axonal degeneration.
• Rituximab therapy has been proposed as a potential treatment for CIDP, but conclusive evidence is lacking.

Purpose of the Study:

• To evaluate the efficacy of rituximab therapy in patients with refractory CIDP.
• To assess the impact of rituximab on neuromuscular function and disability in CIDP patients.

Main Methods:

• Eleven patients with refractory CIDP were treated with rituximab.
• Neuromuscular Medical Research Council (MRC) sum scores, Inflammatory Neuropathy Cause and Treatment (INCAT) disability scores, and functional status were assessed before and after therapy.

Main Results:

• All patients demonstrated improvement in MRC sum scores, INCAT disability scores, and functional status post-rituximab therapy.
• These findings suggest a beneficial effect of rituximab in this patient cohort.

Conclusions:

• Rituximab therapy appears effective in improving outcomes for some patients with CIDP.
• Placebo-controlled trials are necessary to validate these findings and identify biomarkers for treatment responsiveness in CIDP.